e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Palliation and morbidity in lung cancer patients
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cetuximab maintenance therapy – How long should we proceed? A case report
S. Rüdiger, C. Kropf, G. Schmid-Bindert, T. Wibmer, M. Lanzinger, K. Stoiber, J. Blanta, W. Rottbauer, C. Schumann (Ulm, Mannheim, Germany)
Source:
Annual Congress 2011 - Palliation and morbidity in lung cancer patients
Session:
Palliation and morbidity in lung cancer patients
Session type:
Thematic Poster Session
Number:
2777
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Rüdiger, C. Kropf, G. Schmid-Bindert, T. Wibmer, M. Lanzinger, K. Stoiber, J. Blanta, W. Rottbauer, C. Schumann (Ulm, Mannheim, Germany). Cetuximab maintenance therapy – How long should we proceed? A case report. Eur Respir J 2011; 38: Suppl. 55, 2777
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Clinical predictors for long-term benefit of cetuximab maintenance therapy – Single center subanalysis of the GEMTAX IV trial
Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients
Year: 2011
Spontaneous pneumothorax – when, why, how?
Source: Annual Congress 2009 - Pleural and parenchymal diseases
Year: 2009
Monitoring of efficacy of therapy with monoclonal antibodies – Omalizumab – Using the Recovery-ELISA
Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases
Year: 2011
Reimbursed smoking cessation – can we hope for more? One year expertise report
Source: Annual Congress 2009 - Epidemiology of smoking and smoking cessation
Year: 2009
Patients‘ knowledge about inhalation therapy in pulmology – One year after intervention
Source: Annual Congress 2011 - Medical education
Year: 2011
Why are we so poor at following guidelines? – A detailed analysis of a bronchiolitis pathway and its implementation
Source: Annual Congress 2010 - Paediatric epidemiology: infection, prematurity and congenital abnormalities
Year: 2010
Hemoptysis: Causes, interventions and outcomes – Indian single centre experience
Source: Annual Congress 2012 - New insights in the clinical management of lung diseases
Year: 2012
Long term inhalatory therapy in asthma – Achieving control of the disease
Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management
Year: 2012
Smoking assessment & treatment in hospital: Are we providing ‘right care‘ and/or missing cannabis-smoking?
Source: Annual Congress 2011 - Anti-smoking interventions: prevention and treatment
Year: 2011
Ways to shorten the lung clearance index measurement ΙΙ – How long to wash?
Source: Annual Congress 2012 - New developments in paediatric respiratory physiology
Year: 2012
Drug interaction in tuberculosis treatment – The role of pharmacists
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012
Triple 0 – A new respiratory syndrome?
Source: Annual Congress 2012 - Advanced experience with long-term noninvasive ventilation and late-breaking abstracts
Year: 2012
Know it, check it, treat it – COPD consumer mobilisation campaign. A pilot study
Source: Annual Congress 2011 - Quality of diagnosis and assessment in primary care
Year: 2011
Evaluation of difficult asthma – a single centre experience
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Cryptogenic organising pneumonia – clarithromycin treatment – factors influencing treatment results and relapses
Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease
Year: 2009
Pulmonary rehabilitation in advanced lung cancer patients during chemotherapy – Preliminary report
Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care
Year: 2012
Late Breaking Abstract: Inhalation technique errors and education effects in the group of patients using Aerolizer® – The real life study
Source: Annual Congress 2010 - Medical education: methodology
Year: 2010
How should we investigate the child with difficult asthma – Is there any evidence?
Source: Annual Congress 2010 - Quality of life, asthma control and monitoring childhood asthma
Year: 2010
EGFR – a useful biomarker?
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept